Loading...
•
Dec 31, 2020
IDEXX Q4 2020 Earnings Report
IDEXX reported a revenue increase of 19% and EPS increase of 93% for Q4 2020.
Key Takeaways
IDEXX Laboratories announced strong Q4 and full year 2020 results, driven by high growth in Companion Animal Group (CAG) Diagnostics recurring revenue and sustained growth in the Livestock, Poultry and Dairy (LPD) business. Q4 revenue increased by 19% and EPS increased by 93%.
Achieved fourth quarter reported revenue growth of 19% and organic growth of 17%.
CAG Diagnostics recurring revenue reported growth of 23% and organic growth of 21%.
Full year EPS of $6.71, an increase of 37% on a reported basis.
Provided initial outlook for 2021 revenue of $3,065 million - $3,120 million, reflecting reported growth of 13% - 15.5%.
Revenue by Segment
Revenue by Geographic Location
Forward Guidance
The Company expects full year 2021 revenue growth of 13% - 15.5% on a reported basis and 11.5% - 13.5% revenue growth on an organic basis. The Company also expects EPS of $7.39 - $7.71, reflecting a targeted 50 - 100 basis points of comparable constant currency operating margin improvement, building on strong 2020 performance.
Positive Outlook
- Revenue growth rate impact 1.5%-2.0%
- CAG Diagnostics recurring revenue growth rate impact ~ 1.5%
- Operating margin growth impact ~ 10 bps
- EPS impact ~ $0.14
- EPS growth impact ~ 2.0%
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...